Epstein-Barr virus: the antibody response is very ineffective
who – which Epstein Barr virus (EBV) is widespread. In most cases, there are no consequences of infection with pathogens, but the virus can also cause serious diseases. Researchers now report that antibody response Unexpected compared to other viruses inactive he is.
injury Epstein Barr virusEBV, for short, usually occurs in young childhood, then its course is usually asymptomatic and has no consequences in most people. However, the virus can also cause serious illnesses. It is known to cause about 200,000 cases of cancer worldwide each year, reports the German Center for Infection Research (DZIF). However, the antibody response to this pathogen is weak and/or short-lived, as reported in the journal “Pathogens PLOSThe published study appears.
Infection persists for life
More than 90 percent of the population will be infected with Epstein-Barr virus (EBV) during their lifetime. Severe infection with the virus can cause glandular fever, which usually affects the general health of the infected person for a few weeks, the University of Duisburg-Essen (UDE) wrote in a recent case. message.
However, the body is not able to completely eliminate EBV infection, so this whole life consists. While for most sufferers, this chronic viral infection has no other side effects, some sufferers tend to develop certain types of cancer.
former Strategies To develop a vaccine against EBV aimed at stimulating so-called neutralizing antibodies, which bind to viruses in order to prevent infection of cells.
However, this strategy so far has only been able to relieve the symptoms of glandular fever, but Does not prevent infection will.
The virologist from the UDE School of Medicine’s HIV Research Institute, along with colleagues from the American Ragon Institute at MGH, MIT and Harvard, took a closer look at how the antibody responds in a path EBV infection has been developed in detail.
According to the information, through this work a better understanding about whether other immune functions, which are also stimulated by antibodies, can be considered as the basis for the new vaccination strategy.
Poor response to antibodies
The researchers found that the antibody response was weak and/or short-lived compared to other known viruses. “In the first year of infection, only one in four were tested EBV . proteins Develop a functional antibody responseJunior Professor Kristina Carsten, first author of the study, explains.
“In principle, an antibody response can lead to Devastation from infected cells and may play an important role in controlling the active replication of the virus in the acute phase of infection”According to the world.
“But even if it is developed in all the people tested, it is clearly not enough in its naturally induced form to stop infection To extinguish effectively. “
Significant differences in the previously described results
The researchers also found evidence that more than a year after infection, Additional weak antibody functions It matures against other EBV proteins.
Authors deducereported that EBV can induce many antibody responses not previously described. It is possible that this type of antibody response could be stimulated and exploited as part of a new vaccine strategy.
“The antibody response to EBV differs markedly from what was previously described using the same technique for all other viruses studied.”Jun.-Prof. said. Karsten. “Our data indicates that EBV with Mechanisms are still unknown It prevents the formation of a protective antibody response. “
According to the experts, future studies should show whether newly described antibody responses actually contribute to this. Schutz Against EBV infection and its consequences. (ad)
Author and source information
This text conforms to specifications in the specialized medical literature, medical guidelines and current studies and has been verified by medical professionals.
- University of Duisburg-Essen: Epstein-Barr virus: Unexpectedly ineffective antibody response, (Accessed 10 Oct 2022), University of Duisburg-Essen
- Christina B. Carsten, Yannick C. Partch, Sally A. Sheen, Matthew D.; Sline, Howard M. Heller, Kumaran, Kolandaivelo, Yap M. ; In: PLOS Pathogens, (veröffentlicht: 06.09.2022), Pathogens PLOS
- German Center for Infection Research: Epstein-Barr Virus: DZIF and Helmholtz Munich are developing a vaccine, (Accessed 10 October 2022), German Center for Infection Research
This article contains general advice only and should not be used for self-diagnosis or treatment. It cannot replace a visit to the doctor.